Why the study?
Primary malignant cardiac tumors have an extremely poor prognosis, and dedicated evidence-based recommendations are limited due to their rarity and heterogeneity.
Population
17 PMCT patients, 17 healthy controls, and 17 benign cardiac tumor controls in China
Comparison
PMCT patients vs healthy controls vs benign cardiac tumor controls for exploratory laboratory comparisons
Design
Single-center retrospective cohort study
Answers are grounded in this paper and cite their sources.
Dismal survival in primary malignant cardiac tumors warrants cautious counseling; leaves open LDH as biomarker pending multicenter prospective validation.
Background Primary malignant cardiac tumors (PMCTs) are malignancies with extremely poor prognosis. Due to their rarity and heterogeneity, dedicated evidence‐based recommendations are limited. This study aimed to enrich the clinical data of this rare disease and explore potential patterns of its clinical features and outcomes in a single‐center Chinese cohort. Methods We enrolled a PMCT patient cohort from the Affiliated Hospital of Qingdao University from January 1, 2014, to December 30, 2025, covering demographics, imaging, pathology, ECG, laboratory parameters, treatment, and prognosis. Descriptive statistics and exploratory survival analyses were performed, with Firth‐corrected univariable Cox regression. Seventeen healthy controls (HCs) and 17 benign cardiac tumor (BCT) controls were randomly selected without age or sex matching for exploratory laboratory comparisons. Results Seventeen PMCT patients were enrolled: 10/17 (58.8%) were male, the median age was 53 years, and median overall survival (OS) was 4.0 months. All patients were symptomatic at diagnosis, with chest tightness alone being the most common chief complaint (10/17, 58.8%). Angiosarcoma accounted for 11/17 cases (64.7%), and distant metastasis was present in 7/17 (41.2%). Elevated serum LDH (> 245 U/L) was found in 10/17 (58.8%). LDH was higher than in both selected control groups and showed exploratory discrimination (AUC 0.862 against HC and 0.824 against BCT). Only two patients achieved R0 resection, and two had documented postoperative systemic therapy; their outcomes were described individually. Conclusions PMCT was associated with poor survival in this hospital‐based cohort. LDH was higher than in selected controls; its clinical relevance requires validation. R0 resection was uncommon, and postoperative systemic therapy was documented in two patients. Large retrospective cohorts integrating published studies or multicenter prospective clinical studies are warranted.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: